Abstract
The co-incubation of morin hydrate with either doxorubicin or mitomycin C could minimize the toxicity of these anti-tumor drugs on cardiovascular cells, such as red blood cells, human umbilical vein endothelial cells (ECV304) and primary mouse cardiomyocytes, whereas morin hydrate did not lower the cytotoxicity of the drugs on human hepatocellular carcinoma cells (HepG2). Morin hydrate may not exert its antioxidant effect by enhancing the antioxidant enzymatic activity because it did not cause any induction on the mRNA levels of manganese superoxide dismutase expression in ECV304 cells and HepG2 cells.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antioxidants / pharmacology*
-
Carcinoma, Hepatocellular / drug therapy
-
Carcinoma, Hepatocellular / enzymology
-
Carcinoma, Hepatocellular / pathology
-
Cell Survival / drug effects
-
Cytoprotection / drug effects*
-
Doxorubicin / toxicity*
-
Endothelium, Vascular / cytology
-
Endothelium, Vascular / drug effects*
-
Endothelium, Vascular / enzymology
-
Erythrocytes / drug effects
-
Flavonoids / pharmacology*
-
Free Radicals / toxicity
-
Heart / drug effects*
-
Humans
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / enzymology
-
Liver Neoplasms / pathology
-
Mice
-
Mitomycin / toxicity*
-
Myocardium / cytology
-
RNA, Messenger / metabolism
-
Superoxide Dismutase / genetics
-
Tumor Cells, Cultured
-
Umbilical Veins / cytology
-
Umbilical Veins / drug effects
-
Umbilical Veins / enzymology
Substances
-
Antioxidants
-
Flavonoids
-
Free Radicals
-
RNA, Messenger
-
Mitomycin
-
Doxorubicin
-
morin
-
Superoxide Dismutase